AKT1 and breast cancer: Previous studies show that ipatasertib treatment enhanced the phosphorylation level of Akt in breast cancer (BT474) and some other cancer cells38,54,55, while recent report claims that ipatasertib stimulation decreased Akt phosphorylation in several different breast cancer cells even in the same cell line (BT474) as that in previous studies.